Open AccessTreatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia
Author(s) -
Laura Gabriela SánchezLozada,
Edilia Tapia,
V. Soto,
Carmen Ávila-Casado,
Martha Franco,
Lin Zhao,
Richard J. Johnson
Publication year - 2007
Publication title -
nephrology dialysis transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.654
H-Index - 168
eISSN - 1460-2385
pISSN - 0931-0509
DOI - 10.1093/ndt/gfm783
Subject(s) - febuxostat , medicine , xanthine oxidase inhibitor , afferent arterioles , hyperuricemia , allopurinol , uric acid , endocrinology , blood pressure , arteriole , xanthine oxidase , uricosuric , angiotensin ii , microcirculation , chemistry , biochemistry , enzyme
Experimentally-induced hyperuricaemia [due to inhibition of uricase with oxonic acid (OA)] in rats causes hypertension and renal alterations which can be prevented by lowering uric acid (UA) with allopurinol. Febuxostat (Fx), an investigational, nonpurine and selective xanthine oxidase inhibitor, is a more effective UA-lowering agent than allopurinol. We therefore tested the hypothesis that Fx might be useful in treating hyperuricemia-induced hypertension and renal damage.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom